Cytokinetics Stock Performance
| CYTK Stock | USD 61.99 0.02 0.03% |
On a scale of 0 to 100, Cytokinetics holds a performance score of 13. The firm shows a Beta (market volatility) of 0.18, which signifies not very significant fluctuations relative to the market. As returns on the market increase, Cytokinetics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Cytokinetics is expected to be smaller as well. Please check Cytokinetics' value at risk, as well as the relationship between the skewness and day median price , to make a quick decision on whether Cytokinetics' price patterns will revert.
Risk-Adjusted Performance
Good
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Cytokinetics are ranked lower than 13 (%) of all global equities and portfolios over the last 90 days. Despite quite uncertain basic indicators, Cytokinetics disclosed solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 0.0323 | Five Day Return 6.9 | Year To Date Return 26.69 | Ten Year Return 599.66 | All Time Return (35.83) |
Last Split Factor 1:6 | Last Split Date 2013-06-25 |
1 | Disposition of 5000 shares by Robert Blum of Cytokinetics at 38.42 subject to Rule 16b-3 | 08/15/2025 |
2 | Disposition of 5000 shares by Robert Blum of Cytokinetics at 49.77 subject to Rule 16b-3 | 09/15/2025 |
3 | Cytokinetics, Incorporated Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit | 10/07/2025 |
4 | November 17, 2025 Deadline Contact The Gross Law Firm to Join Class Action Suit Against CYTK | 10/13/2025 |
5 | Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635 | 10/17/2025 |
6 | Contact The Gross Law Firm by November 17, 2025 Deadline to Join Class Action Against Cytokinetics, Incorporated | 10/20/2025 |
7 | Cytokinetics, Incorporated Securities Fraud Class Action Lawsuit Pending Contact The Gross Law Firm Before November 17, 2025 to Discuss Your Rights CYTK | 10/22/2025 |
8 | Does Litigation Over FDA Risk Disclosures Alter the Bull Case for Cytokinetics | 10/23/2025 |
9 | INVESTOR ALERT Pomerantz Law Firm Reminds Investors with Losses on their Investment in Cytokinetics, Incorporate of Class Action Lawsuit and Upcoming Deadlines ... | 10/24/2025 |
10 | Cytokinetics Examining Valuation After Class Action Lawsuit Raises Regulatory Risk Concerns | 10/27/2025 |
11 | CYTOKINETICS CLASS ACTION REMINDER Bragar Eagel Squire, P.C. Urgently Reminds CYTK Investors to Contact the Firm Before November 17th | 10/29/2025 |
| Begin Period Cash Flow | 113.4 M | |
| Total Cashflows From Investing Activities | -553.1 M |
Cytokinetics | Build AI portfolio with Cytokinetics Stock |
Cytokinetics Relative Risk vs. Return Landscape
If you would invest 3,669 in Cytokinetics on August 1, 2025 and sell it today you would earn a total of 2,530 from holding Cytokinetics or generate 68.96% return on investment over 90 days. Cytokinetics is currently generating 0.9807% in daily expected returns and assumes 5.8926% risk (volatility on return distribution) over the 90 days horizon. In different words, 52% of stocks are less volatile than Cytokinetics, and 81% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Cytokinetics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Cytokinetics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Cytokinetics, and traders can use it to determine the average amount a Cytokinetics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1664
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | CYTK | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 5.89 actual daily | 52 52% of assets are less volatile |
Expected Return
| 0.98 actual daily | 19 81% of assets have higher returns |
Risk-Adjusted Return
| 0.17 actual daily | 13 87% of assets perform better |
Based on monthly moving average Cytokinetics is performing at about 13% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Cytokinetics by adding it to a well-diversified portfolio.
Cytokinetics Fundamentals Growth
Cytokinetics Stock prices reflect investors' perceptions of the future prospects and financial health of Cytokinetics, and Cytokinetics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Cytokinetics Stock performance.
| Return On Equity | -5.72 | ||||
| Return On Asset | -0.25 | ||||
| Operating Margin | (1.67) % | ||||
| Current Valuation | 6.74 B | ||||
| Shares Outstanding | 119.66 M | ||||
| Price To Earning | (37.76) X | ||||
| Price To Book | 60.31 X | ||||
| Price To Sales | 86.51 X | ||||
| Revenue | 18.47 M | ||||
| Gross Profit | (304.9 M) | ||||
| EBITDA | (493.48 M) | ||||
| Net Income | (589.53 M) | ||||
| Cash And Equivalents | 586.03 M | ||||
| Cash Per Share | 6.22 X | ||||
| Total Debt | 788.68 M | ||||
| Debt To Equity | 2.93 % | ||||
| Current Ratio | 9.01 X | ||||
| Book Value Per Share | (3.08) X | ||||
| Cash Flow From Operations | (395.89 M) | ||||
| Earnings Per Share | (5.12) X | ||||
| Market Capitalization | 7.42 B | ||||
| Total Asset | 1.4 B | ||||
| Retained Earnings | (2.7 B) | ||||
| Working Capital | 928.27 M | ||||
| Current Asset | 113.11 M | ||||
| Current Liabilities | 31.65 M | ||||
About Cytokinetics Performance
By examining Cytokinetics' fundamental ratios, stakeholders can obtain critical insights into Cytokinetics' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Cytokinetics is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | (0.20) | (0.21) | |
| Return On Tangible Assets | (0.42) | (0.44) | |
| Return On Capital Employed | (0.44) | (0.46) | |
| Return On Assets | (0.42) | (0.44) | |
| Return On Equity | 4.35 | 4.57 |
Things to note about Cytokinetics performance evaluation
Checking the ongoing alerts about Cytokinetics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Cytokinetics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Cytokinetics is way too risky over 90 days horizon | |
| Cytokinetics appears to be risky and price may revert if volatility continues | |
| The company reported the previous year's revenue of 18.47 M. Net Loss for the year was (589.53 M) with loss before overhead, payroll, taxes, and interest of (304.9 M). | |
| Cytokinetics currently holds about 586.03 M in cash with (395.89 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.22. | |
| Cytokinetics has a frail financial position based on the latest SEC disclosures | |
| Over 99.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from thefly.com: Johnson Johnson in talks to buy Protagonist Therapeutics, WSJ reports JNJPTGX |
- Analyzing Cytokinetics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Cytokinetics' stock is overvalued or undervalued compared to its peers.
- Examining Cytokinetics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Cytokinetics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Cytokinetics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Cytokinetics' stock. These opinions can provide insight into Cytokinetics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cytokinetics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. For more information on how to buy Cytokinetics Stock please use our How to buy in Cytokinetics Stock guide.You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cytokinetics. If investors know Cytokinetics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cytokinetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (5.12) | Revenue Per Share | Quarterly Revenue Growth 267.149 | Return On Assets | Return On Equity |
The market value of Cytokinetics is measured differently than its book value, which is the value of Cytokinetics that is recorded on the company's balance sheet. Investors also form their own opinion of Cytokinetics' value that differs from its market value or its book value, called intrinsic value, which is Cytokinetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cytokinetics' market value can be influenced by many factors that don't directly affect Cytokinetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cytokinetics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cytokinetics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cytokinetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.